RxDoctor Payments Data

Jason Casey

Nurse Practitioner · Snellville, GANPI 1003291378

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Johnson & Johnson at 40.4% of the total. Among nurse practitioner clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,404in general payments, 2019–2025

Across 154 payments — averaging $93.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$6K
  • Medtronic$4K
  • Boston Scientific$904
  • Antares Pharma, Inc.$409
  • Astellas Pharma US Inc$330
  • Teleflex LLC$311
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$4,59032%
  • Travel & lodging$3,11722%
  • Food & beverage$6,45145%
  • Education$2462%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,404 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$79,014
Medicare patients
265
Services billed
4,446

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron162$173,221
GemtesaVibegron15$12,773
Testosterone64$6,254
Tamsulosin Hcl343$4,929
Solifenacin Succinate73$3,554
Testosterone Cypionate73$2,621
Potassium Citrate ErPotassium Citrate33$2,340
Methenamine Hippurate16$1,828
Trospium Chloride ErTrospium Chloride12$1,456
Finasteride106$1,332
Trospium Chloride20$1,282
Darifenacin ErDarifenacin Hydrobromide11$1,112
Oxybutynin Chloride ErOxybutynin Chloride52$1,051
Silodosin16$1,033
Alfuzosin Hcl ErAlfuzosin Hcl39$723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$330$173,221162 claims
Sumitomo Pharma America, Inc.Gemtesa$185$12,77315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →